Victory Over Neurodegeneration
Impaired autophagy-lysosomal pathway (ALP) is a key component in the etiology of genetically defined CNS dysfunction. Based on technologies from leading scientific institutions, we are launching a new biotechnology company developing CNS-directed gene therapies to address ALP dysfunction in genetically defined neurodegenerative diseases, including Alzheimer's, Parkinson's and frontotemporal dementia.
For more information, please contact us using the form below. Thank you!
611 Gateway Blvd Suite 120, South San Francisco, CA 94080
136 E Rosemary Suite 100, Chapel Hill, NC 27514